Tatva Chintan Pharma Chem Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 26, 2025

Tatva Chintan Pharma Chem held its 29th Annual General Meeting on September 26, 2025, via video conferencing, and has submitted the scrutinizer's report of voting results to the exchanges. All 12 resolutions were passed with the requisite majority. Key items approved include the adoption of audited standalone and consolidated financial statements for FY ended March 31, 2025, and the declaration of a dividend on equity shares. Shareholders also approved the re-appointment of Mr. Ajaykumar Mansukhlal Patel (as Director retiring by rotation), Mr. Chintan Nitinkumar Shah as Managing Director, Mr. Patel and Mr. Shekhar Rasiklal Somani as Whole-time Directors, and three Independent Directors (Mr. Subhash Ambubhai Patel, Mr. Manher Chimanlal Desai, and Mrs. Avani Rajesh Umatt) for one-year terms effective February 1, 2026. The appointment of Secretarial Auditors and ratification of Cost Auditor remuneration for FY 2025-26 were also cleared. Most resolutions passed with over 99.99% approval; the Managing Director re-appointment saw the highest dissent at around 3.09%. Total voting turnout was about 79% of paid-up share capital.